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Abstract:  Mouse mammary tumor virus (MMTV), which was discovered as a 
milk-transmitted, infectious cancer-inducing agent in the 1930s, has been used since that 
time as an animal model for the study of human breast cancer. Like other complex 
retroviruses, MMTV encodes a number of accessory proteins that both facilitate infection 
and affect host immune response. In vivo, the virus predominantly infects lymphocytes and 
mammary epithelial cells. High level infection of mammary epithelial cells ensures 
efficient passage of virus to the next generation. It also results in mammary tumor 
induction, since the MMTV provirus integrates into the mammary epithelial cell genome 
during viral replication and activates cellular oncogene expression. Thus, mammary tumor 
induction is a by-product of the infection cycle. A number of important oncogenes have 
been discovered by carrying out MMTV integration site analysis, some of which may play 
a role in human breast cancer. 
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1. Introduction 
Non-acute transforming retroviruses, which cause dysregulated expression of cellular oncogenes 
upon integration of the provirus into the host genome, have long been used to study both tumor 
development and progression in animal models [1]. Indeed, many oncogenes were originally identified 
because of their association with tumors caused by this type of retrovirus. Although the majority of 
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non-acute transforming retroviruses induce cancer in cells of hematopoietic origin, one exception is the 
murine betaretrovirus MMTV, which causes mammary epithelial cell tumors. MMTV was first 
characterized in the 1930s as a milk-transmitted agent associated with mammary tumors in mice [2] 
and thus has long been used as an in vivo model for the study of human breast cancer [3]. Here, I 
briefly review MMTV molecular biology, its in vivo infection pathway, and what has been learned 
about how this virus causes mammary tumors. 
2. MMTV genome and proteins 
MMTV was originally classified as a simple retrovirus. The genomes of simple retroviruses encode 
the virion capsid/nucleocapsid (Gag) proteins, the enzymes needed for genome replication (reverse 
transcriptase and integrase; Pol/In) and the envelope proteins (Env) that bind the cell surface 
molecule(s) used for virus entry [1]. In contrast, the genomes of complex retroviruses, such as 
lentiviruses and deltaviruses, encode non-structural proteins that facilitate virus replication or that 
counteract intrinsic, innate or adaptive immune responses during in vivo infection. Because the MMTV 
genome encodes at least three known accessory proteins that carry out these functions, it is now 
considered a complex retrovirus. 
The MMTV is 9 kb in length and like all retroviruses, is flanked by 5ʹ and 3ʹ long terminal repeats 
(LTRs), which in the case of MMTV are exceptionally long (approximately 1.3 kb). This is because 
the MMTV 3ʹ LTR encodes one of the viral accessory proteins, termed the superantigen (Sag) 
(Figure 1). In addition to the Sag coding region, there are a number of transcription factor binding sites 
in the LTR that determine tissue-specific, as well as glucocorticoid/progesterone-regulated virus 
expression [4-6]. Because they direct high level, hormone regulated expression in mammary epithelial 
cells, the MMTV LTRs have been extensively used to drive oncogene expression in transgenic mice as 
a means of creating mouse models of breast cancer [3]. Similarly, mammary gland-specific deletion of 
tumor suppressor genes using MMTV LTR-cre recombinase transgenic mice has resulted in additional 
breast cancer models [7].  
MMTV also infects lymphocytes in vivo (see next section) and the MMTV LTRs contain regulatory 
elements that control expression in B and T cells [8,9]. Thus, MMTV-oncogene transgenic mice 
frequently develop lymphoid as well as mammary cell tumors (for example, see [10]). Although 
MMTV infects and is expressed in lymphocytes, the virus usually only causes mammary tumors. 
However, there are MMTV variants with deletions/insertions in the LTRs that are causally associated 
with T cell lymphomas; the sequence alterations in the LTR are believed to result in the generation of 
transcriptional enhancers that activate linked cellular oncogene expression in these cells [11,12]. 
At least five transcripts are generated from the MMTV genome. A full-length, unspliced RNA that 
initiates in the 5ʹ LTR and terminates in the 3ʹ LTR serves as the viral genome and is packaged into 
virions [1]. This transcript also functions as the mRNA for the Gag and Pol proteins, as well as a 
dUTPase (Dut) and other proteins of unknown function (Figure 1). The role of the dUTPase in MMTV 
infection is not known, but the Dut of the lentivirus equine infectious anemia virus (EIAV) is thought 
to facilitate replication of EIAV in non-dividing cells by maintaining adequate nucleotide pools [13]. Viruses 2010, 2                                       
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Figure 1. MMTV infection. MMTV binds to TfR1 on the cell surface and is internalized 
into a low pH compartment. After uncoating, the viral genome is reverse-transcribed, is 
transported to the nucleus, and the provirus integrates into the genome. At least five 
different RNAs are transcribed from the integrated provirus (see text). The Env membrane 
proteins are synthesis in the rough endoplasmic reticulum (RER) and traffic through the 
Golgi network (GN). Little is known about MMTV virion assembly, although it occurs in 
an intra-cellular compartment. Abbreviations: E, endosome; EE, early endosome; LE, late 
endosome. 
 
 
The Env protein, which mediates retroviral entry into cells by binding specific cell surface 
molecules, is encoded by a singly spliced mRNA (Figure 1). As with other retroviruses, the MMTV 
Env consists of two chains, generated by cellular furin processing of a 73 kD polyprotein precursor to 
a 52 kD cell surface (SU) protein, which binds the entry receptor, and a 36 kD transmembrane (TM) 
domain that is responsible for membrane fusion. MMTV uses transferrin receptor 1 (TfR1) for 
entry [14]. TfR1, the major means by which cells take up iron [15], traffics to the acidic endosome 
upon ligand (iron-bound transferrin) binding. MMTV entry requires low pH (<5.2) and thus, most 
likely co-traffics with TfR1 to a late endosomal compartment after binding at the cell surface [14,16] 
(Figure 1). TfR1 is highly expressed on activated lymphocytes and dividing mammary epithelial cells 
in vivo, which probably limits MMTV infection to these cell types [17-19]. Additionally, as described Viruses 2010, 2                                       
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above, the transcriptional regulatory elements in the MMTV LTR function predominantly in mammary 
epithelia and lymphoid cells, thus further restricting infection and spread to other tissues in vivo.  
At least two additional accessory genes, Sag and Rem, are encoded by other alternatively spliced 
mRNAs (Figure 1). The Sag protein is translated from two different transcripts (Figure 1). The first 
transcript initiates in the 5ʹ LTR and uses the same splice donor as the env mRNA. The second 
transcript uses a promoter and splice donor in env. Both transcripts use a splice acceptor just upstream 
of the open reading frame in the 3ʹ LTR [20-22]. The regulator of export of MMTV (Rem) protein is 
encoded by a double spliced mRNA [23,24]. Like the human immunodeficiency virus (HIV) Rev 
protein, Rem is required for efficient transport of unspliced viral RNA from the nucleus through 
interaction with a Rem-responsive element present in the MMTV RNA [25,26]. 
As is the case for other betaretroviruses, MMTV virion assembly occurs in an intracellular 
compartment and virions are then exported to the plasma membrane for egress from the cell [27]. 
However, little is known about either the viral or cellular requirements for MMTV assembly. In vivo, 
virus is shed from the apical surface of polarized mammary epithelial cells into the lumen of the end 
buds, along with the milk proteins and thus is transmitted to offspring [28]. 
3. MMTV in vivo infection  
MMTV is transmitted from infected mothers to pups through nursing, most likely as cell-free virus 
which is present at very high levels in milk [29]. Susceptible strains that acquire exogenous MMTV 
through milk can be freed of the virus by foster-nursing on uninfected mothers. Viruses isolated from 
mice that shed milk-borne MMTV infect and cause tumors in different strains of mice to varying 
degrees [30]. This differential susceptibility to MMTV infection is due in large part to intrinsic, innate 
and adaptive immune responses to the virus that vary between mouse strains (see below). In addition to 
the exogenous form of MMTV, all commonly used inbred mice as well as many wild mice inherit 
endogenous copies of MMTV which are thought to have entered the mouse genome between   
10–20 million years ago [31]. The vast majority of endogenous MMTVs do not produce infectious 
virus due to deletions or mutations in the proviral genome. At least 10 different exogenous and greater 
than 30 endogenous MMTVs have been identified (for example, see [32-35]).  
With the exception of the virions found in milk, exogenous MMTV in infected mice is 
cell-associated [36] and infection of lymphocytes is critical for virus spread from the gut to the 
mammary tissue (reviewed in [37]). In brief, MMTV acquired through milk first infects dendritic cells 
(DCs) then spreads to T and B cells in the Peyer’s patches of the gut and ultimately to other lymph 
nodes and lymphoid organs. This spread is largely due to the viral Sag protein, which is presented to 
the T cell (TCR) on CD4+ T cells by major histocompatibility (MHC) class II proteins expressed on 
the surface of infected antigen presenting cells, such as DCs and B cells. The Sag-activated T cells 
proliferate, provide B cell help and produce cytokines that stimulate and recruit additional DCs, B and 
T cells, resulting in the establishment of a reservoir of infection-competent and infected lymphocytes. 
The mammary gland is considered mucosal-associated lymphoid tissue (MALT) and represents a site 
of normal lymphocyte trafficking. MMTV-infected lymphocytes are therefore not only an important 
reservoir for amplification of the virus in vivo, but also carry virus to the mammary gland [38,39]. Viruses 2010, 2                                       
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MMTV infects mammary epithelial cells at a time when they are driven to divide, that is, during the 
cell division that accompanies both puberty and pregnancy. Mice that go through multiple rounds of 
pregnancy have much higher levels of MMTV infection in mammary tissue [36]. It is believed this is 
due to the increased susceptibility of dividing mammary epithelial cells to infection by   
lymphocyte-produced virus and not to horizontal spread of the virus between mammary cells [38]. 
Transcription of viral RNA and production of virus is highest during late lactation and pregnancy, 
thereby maximizing virion production in milk. 
Different exogenous and endogenous MMTVs encode Sag proteins with different TCR specificity. 
Sags encoded by endogenous MMTVs cause the deletion of cognate T cells during shaping of the 
immune repertoire, while those encoded by exogenous virus produce a slower but none-the-less almost 
complete deletion of such lymphocytes [40]. This results in mice that are immune to infection by 
exogenous MMTVs with the same Sags because they lack responding T cells [41]. MMTV 
Sag-induced T cell deletion may also make some mouse strains more resistant to the pathogenic effects 
of Leishmania major because of loss of T cell responses [42]. Interestingly, while most of the 
endogenous MMTVs sustain mutations in the coding regions for the virion proteins, almost all retain 
intact Sag coding regions, suggesting that the anti-viral and -parasite protection might confer a 
selective advantage to mice that retain endogenous MMTVs. 
There are other host genes that confer resistance or susceptibility to MMTV. These include MHC 
Class II genes required for efficient Sag presentation, the innate immune pathogen sensor toll-like 
receptor 4 (Tlr4), and several as-of-yet unidentified genes that affect the production of anti-MMTV 
antibodies or T cell responses to MMTV (reviewed in [43]). MMTV infection is also restricted by the 
intrinsic immune factor, apolipoprotein B editing complex 3 (APOBEC3) [44]. Different inbred mouse 
strains have polymorphisms in Apobec3 [45], which affect the ability of this factor to inhibit MMTV 
infection [46]. All of the host genes that affect MMTV lymphocyte infection also alter the incidence 
and kinetics of mammary tumor induction. Interestingly, host genes that affect mammary 
tumorigenesis do so by limiting virus infection; none have been shown to have a direct effect on the 
ability of the virus to transform mammary epithelial cells.  
4. MMTV and Mammary Tumorigenesis 
MMTV-induced mammary tumorigenesis is mediated by proviral integration, usually by 
enhancer -mediated activation of nearby cellular oncogenes, although a few examples of coding region 
insertions that alter the gene product have also been described [47]. Additionally, the MMTV Env 
protein has been implicated in mammary tumorigenesis. The MMTV Env has an immuno-tyrosine 
based activation motif (ITAM) commonly found in receptors expressed in hematopoietic cells; 
expression of the Env protein in normal mouse or human mammary epithelial cells induces 
morphological transformation in culture [48]. Moreover, when the ITAM motif was mutated in the 
virus, mammary tumor-induction was attenuated in infected mice [49]. 
In vivo infection levels usually affect mammary tumor incidence and kinetics because of an 
increased number of proviral integrations. A number of different common integration sites (CIS) have 
been implicated in MMTV-induced mammary tumors (Table 1), particularly the Wnt and Fgf 
genes  [47]. MMTV-induced tumors appear to develop from infection of a single stem cell [50]. Viruses 2010, 2                                       
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Mammary stem cells have the potential to form two epithelial lineages in the mammary gland, 
myoepithelial cells found on the outside of ducts, and ductal and alveolar luminal cells. MMTV-
induced tumors proceed through at least two stages, the pregnancy-dependent hyperplastic alveolar 
nodule (HAN), followed by the hormone-independent mammary tumor [51]. Although the 
histopathological features of MMTV-induced tumors do not usually resemble the most frequent forms 
of human breast tumors such as invasive ductal carcinomas, many, if not all, of the human mammary 
lesions are thought to originate in the terminal ductal lobular unit and atypical lobular type A lesions 
(ALA) are morphologically similar to the mouse mammary HAN lesions [51].  
Most MMTV-induced mammary tumors contain 10 or more proviral integrations [51]. Whether 
MMTV-induced mammary tumors are the result of a single initiating integration or are a composite of 
multiple integrations is currently unclear, although it appears that progression of tumors from a 
pregnancy-dependent to a pregnancy-independent state depends on additional integration events and 
that the former frequently arise as polyclonal populations while the latter are generally 
monoclonal [34,52]. That mammary tumorigenesis requires the activation of multiple oncogenes is 
supported by several observations. First, a large percentage of mammary tumors derived from 
MMTV-infected wild type mice have “hits” at both Wnt1 and Fgf3; it is likely that additional genes are 
activated in these tumors. Second, the creation of double transgenic mice, such as   
MMTV-Wnt1/MMTV-Fgf3 accelerates the induction of mammary tumors [53-55]. Similarly, 
tumorigenesis is accelerated by MMTV infection of transgenic mice with genetic predisposition to 
mammary tumorigenesis, such as those that express the Wnt1, c-neu or TGF transgenes in mammary 
tissue [54,56].  
Table 1. MMTV common integration sites. 
Mouse   Oncogene  Reference
Wild type  Wnt1/Wnt10b [57] 
Wild type  Fgf3 [58] 
Wild type  Fgf10 [59] 
MMTV-Wnt1 Fgf8 [55] 
Wild type  Notch4 [60] 
Wild type  int-5/aromatase [61] 
MMTV-neu  Notch1 [56] 
WAP-TGF   Wnt1/Wnt3 [62] 
Wild type  eIF3e-p48  [63] 
Wild type  Rspo2 [64] 
Wild type  Rspo3 [65,66] 
 
The oncogenes listed in Table 1 were identified by infection of both wild type and transgenic mice 
expressing oncogenes in mammary tissue. Although most of the CIS listed in Table I were identified 
through low throughput analyses, more recently, high throughput analysis of MMTV insertion sites has 
been performed and uncovered gene families not previously associated with cancer [66]. MMTV target 
site analysis has great potential for uncovering pathways relevant to the human disease, particularly in Viruses 2010, 2                                       
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transgenic strains with tumor morphology similar to that seen in humans. Even though 
MMTV-induced mammary tumors do not morphologically resemble most human breast cancers, there 
are molecular similarities between the mouse and human disease. For example, although Wnt1 itself 
has not been implicated in human breast cancer, other members of this family as well as targets of the 
Wnt signaling pathway, such as -catenin, E-cadherin, cyclin D1, etc., are known to be mutated or 
deregulated in a number of human cancers [67,68] and several Fgf family members have been 
implicated in human breast cancer [59,69]. Moreover, a number of the novel CIS uncovered in the high 
throughput screens were found to be dysregulated in human breast cancer and correlated with one or 
more clinical parameters in the human tumors, such as angioinvasion, tumor grade or lymphatic 
infiltration, as well as metastasis [66]. 
Since the discovery of MMTV, numerous investigators have searched for a similar virus in human 
breast cancers (see [70] and [37] for a more extensive review). Early studies using immunological 
assays detected antibodies against MMTV proteins in sera from human breast cancer patients, but were 
later shown to be most likely due to non-specific cross-reactive proteins [71]. Molecular analyses for 
DNA sequences related to MMTV in human DNA resulted in the discovery of the first human 
endogenous retroviruses (HERVs) because of their homology to MMTV, particularly in the pol gene,  
but no MMTV-like sequences were identified [72]. More recently, several groups have used 
polymerase chain reaction (PCR)-based techniques to amplify MMTV-like sequences from human 
breast cancer biopsies [73,74]; however, others have been unable to replicate these studies [75-78]. 
Moreover, it has been reported that MMTV can infect cultured human mammary epithelial cells, but 
MMTV cannot use human transferrin receptor 1 as an entry receptor and thus would have to infect 
cells via a different entry mechanism [14,16,79]. Thus, the existence of a human MTV remains to 
be confirmed. 
5. Conclusions and perspectives  
Much has been learned about in vivo virus infection using MMTV and mice. This is in a large part 
due to our ability to study the natural route of milk-borne transmission and to the use of both inbred 
and genetically altered transgenic and knockout mice in the analysis of infection and oncogenesis. 
Because MMTV has existed as an infectious virus in mice for millions of years, it has evolved to take 
advantage of its host’s biology, using host genes from transcription factors to immune regulatory 
molecules, to establish infection. Although it causes mammary tumors, this does not occur until 
relatively late in life and thus the virus has persisted, since infected mothers are able to transmit virus 
to offspring. The lack of acute MMTV-induced pathogenesis is most likely due to different host means 
of limiting virus infection, including factors that operate at the cellular level like intrinsic restriction 
factors and immune response genes. As additional host-anti-viral genes are discovered, MMTV will 
continue to serve as an important model for testing the ability of these factors to function in vivo. 
In addition to serving as an important means for studying virus infection, MMTV has provided a 
number of critical models for understanding human breast cancer. First, the analysis of MMTV CIS 
has led to the identification of oncogenes/pathways such as members of the Wnt family that are known 
to play roles in different human cancers. Second, ITAM-mediated signaling in mammary epithelial 
cells may represent a novel mechanism of transformation; indeed, a novel oncogene associated with Viruses 2010, 2                                       
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invasive breast cancer in humans has been recently shown to transform cells through ITAM-mediated 
signaling [80]. Finally, the use of the MMTV LTR to direct oncogene expression to murine epithelial 
cells has resulted in the creation of numerous transgenic mouse strains that serve as critical models for 
understanding human breast cancer. It is likely that such transgenic mice will continue to be a critical 
tool as additional human breast cancer genes are identified through large-scale human genetic studies. 
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